Announcements Trials
Browse Landscape

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 23Observational 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 18Cholangiocarcinoma 3Thyroid Neoplasms 2Recurrence 1Neoplasms, Glandular and Epithelial 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Coitus 1Carcinoma, Renal Cell 1Carcinoma 1Biliary Tract Neoplasms 1

Interventions

lenvatinib 3Surgical Procedures, Operative 3Hepatectomy 3Cholangiopancreatography, Endoscopic Retrograde 3Blood Specimen Collection 3Oxaliplatin 2Liquid Biopsy 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Drug Therapy 2Base Sequence 2pembrolizumab 1gemcitabine-oxaliplatin regimen 1envafolimab 1Vascular Endothelial Growth Factor A 1Urination 1Tegafur 1Shadowing Technique, Histology 1S 1 (combination) 1Radiotherapy 1Quality of Life 1Polymerase Chain Reaction 1Photochemotherapy 1Patient Reported Outcome Measures 1Pancreaticoduodenectomy 1Palliative Care 1Observation 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Microbiota 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Cholangiocarcinoma × lenvatinib × Clear all
NCT06648057 2026-03-18

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

CHA University

Recruiting
100 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06643208 2025-06-26

D-TACE-HAIC Combined With Envafolimab and Lenvatinib for Unresectable ICC

Fujian Provincial Hospital

Recruiting
37 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT06505486 2024-07-17

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting
21 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡